Thursday, 27 February 2020, 1221 Avenue of the Americas, New York.

This year’s GCR Live Pharmaceuticals conference, chaired by J. Mark Gidley, White & Case and David Blackburn, NERA Economic consulting, will dissect antitrust hot topics affecting the pharma industry in the US and beyond. On tap is a top-level panel discussion of the latest antitrust enforcement actions intended curtail "killer" pipeline acquisitions in order to protect consumers and competition between drugmakers. It will also delve into drug pricing practices, asking whether legislative remedies are enough to address pricing ills in the market. The conference will close with an update on the current state of antitrust litigation affecting the industry.

The half-day event will provide delegates with the opportunity to network with industry-specific corporate counsel, enforcers, academics and senior private practitioners  who are working on the cases shaping the pharmaceutical sector. Our discussion-led sessions will provide our audience with an informative and interactive debate. We also offer networking breaks where you will meet like-minded individuals from across the US and internationally. 

E-mail Tel: +44 203 780 4157

Chairs

David Blackburn

NERA Economic Consulting, Washington, DC

Dr. Blackburn is a Director and Head of the Life Sciences Group. Dr. Blackburn's areas of expertise include intellectual property (IP), antitrust and competition policy, and econometric analysis. In his IP practice, he conducts research and prepares expert reports for patent, trademark, and copyright infringement disputes, and false and misleading advertising cases.

J. Mark Gidley

White & Case, Washington, DC

J. Mark Gidley chairs the White & Case Global Antitrust/Competition practice, which is the only such practice to have been named Competition Group of the Year for seven years by Law360. His practice focuses on mergers and acquisitions, cartel cases, class actions, and pharmaceutical antitrust cases, with an emphasis on trying antitrust cases.

Speakers

Mike Cowie

Dechert, Washington, DC

Debbie Feinstein

Arnold & Porter, Washington, DC

Elaine Johnston

Allen & Overy, New York

Susan Jones

Gilbert & Tobin, Melbourne

Brianne Kucerik

Weil, Gotshal & Manges, Washington, DC

Chuck Loughlin

Hogan Lovells, Washington, DC

Andrea Agathoklis Murino

Goodwin Procter, Washington, DC

Eric Stock

Gibson, Dunn & Crutcher, New York

Desma Polydorou

Pfizer

Programme

13.00: Welcome coffee and registration

13.30: Chairs’ opening remarks

David Blackburn, NERA, Washington, DC
J. Mark Gidley, White & Case, Washington, DC

13.45: Keynote address

14.15: Killer acquisitions in the pharmaceutical sector

Is current legislation doing enough to protect consumers from the effects of killer acquisitions?  This session will attempt to answer this question with an in-depth look at pipeline acquisitions, and consider whether more could be done to prevent companies from buying-out product lines which could have developed into competition.

Moderator:
Debbie Feinstein, Arnold & Porter, Washington, DC 

Panel:
Susan Jones, Gilbert & Tobin, Melbourne
Brianne Kucerik, Weil, Gotshal & Manges, Washington, DC 
Andrea Agathoklis Murino, Goodwin Procter, Washington, DC

15.15: Coffee break

15.45: Pricing in pharmaceuticals

Increasingly, enforcement agencies are putting more pressure on pharmaceutical manufacturers to ensure their pricing is fair and transparent. As the number of states implementing pricing legislation is surging, it’s clear pricing remains a prominent issue in the pharmaceuticals industry. With focus shifting towards legislative remedies – is it enough? This session will consider whether the current methods in place to tackle pricing issues are adequate when addressing ills in the market.

Moderator:
J. Mark Gidley, White & Case, Washington, DC

Panel:
Mike Cowie, Dechert, Washington, DC
Desma Polydorou, Pfizer, New York 

16.45: An update on pharmaceutical anti-trust litigation  

This session will explore recent pharmaceutical litigation cases and how they are evolving. Our panellists will consider the effect of the Apotex Inc. vs Acorda Therapeutics case on so-called sham litigations, as well as taking a look at developments in blocking patent cases, reverse payment, product hopping and the effect this may have on antitrust.

Moderator:
David Blackburn, NERA, Washington, DC

Panel:
Elaine Johnston, Allen & Overy, New York 
Chuck Loughlin, Hogan Lovells, Washington, DC
Eric Stock, Gibson, Dunn & Crutcher, New York

17.45: Chair’s closing remarks

David Blackburn, NERA, Washington, DC
J. Mark Gidley, White & Case, Washington, DC

18.00: Delegates are invited to attend a drinks reception kindly hosted by White & Case

Venue

1221 Avenue of the Americas, New York, 10020-1095 United States

Testimonials

  • "Very good speakers and presentations." Robert Maness, Charles River Associates

  • "The topics... included the most important issues of competition law facing the pharmaceutical as bio-tech industry today." Ankur Kapoor, Constantine Cannon 

Ticket Prices

Private Practitioner
Type Price Expires
Super Early $350 17 Jan 2020
Early $450 14 feb 2020
Standard $550 27 Feb 2020

 

In-house/government rate
Type Price
Standard $0